Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

Plasma-derived product · developed by Kamada

Phase 2 Most advanced trial (none active)
KMDA Developer
1 Registered trials

What is Aerosolized, human, plasma-derived Alpha-1 Antitrypsin?

Aerosolized, human, plasma-derived alpha-1 antitrypsin is inhaled alpha-1 antitrypsin protein purified from human plasma. It is studied in cystic fibrosis, a respiratory disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Therapy area
Respiratory
Developer
Kamada, Ltd. (KMDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00499837 Phase 2 Cystic Fibrosis Completed KMDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis

More from Kamada

Follow KMDA, the company behind Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KMDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.